

COPS7A Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP12810b**Specification**

COPS7A Antibody (C-term) - Product Information

Application	WB, IHC-P,E
Primary Accession	O9UBW8
Other Accession	O9CZ04 , NP_057403.1
Reactivity	Human
Predicted	Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	30277
Antigen Region	237-266

COPS7A Antibody (C-term) - Additional Information**Gene ID** 50813**Other Names**

COP9 signalosome complex subunit 7a, SGN7a, Signalosome subunit 7a, Dermal papilla-derived protein 10, JAB1-containing signalosome subunit 7a, COPS7A, CSN7A, DERP10

Target/Specificity

This COPS7A antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 237-266 amino acids from the C-terminal region of human COPS7A.

Dilution

WB~~1:1000
IHC-P~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

COPS7A Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

COPS7A Antibody (C-term) - Protein Information**Name** COPS7A

Synonyms CSN7A, DERP10

Function Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of SCF- type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, JUN, I-kappa-B-alpha/NFKBIA, ITPK1 and IRF8/ICSBP, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively.

Cellular Location

Cytoplasm. Nucleus


Tissue Location

Widely expressed. Expressed at high level in brain, heart and skeletal muscle.


COPS7A Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

COPS7A Antibody (C-term) - Images

COPS7A Antibody (C-term) (Cat. #AP12810b) western blot analysis in human placenta tissue lysates (35ug/lane). This demonstrates the COPS7A antibody detected the COPS7A protein (arrow).



COPS7A Antibody (C-term) (Cat. #AP12810b) immunohistochemistry analysis in formalin fixed and paraffin embedded human pancreas tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of COPS7A Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.

COPS7A Antibody (C-term) - Background

Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes. The CSN complex is an essential regulator of the ubiquitin (Ubl) conjugation pathway by mediating the deneddylation of the cullin subunits of SCF-type E3 ligase complexes, leading to decrease the Ubl ligase activity of SCF-type complexes such as SCF, CSA or DDB2. The complex is also involved in phosphorylation of p53/TP53, JUN, I-kappa-B-alpha/NFKBIA, ITPK1 and IRF8/ICSBP, possibly via its association with CK2 and PKD kinases. CSN-dependent phosphorylation of TP53 and JUN promotes and protects degradation by the Ubl system, respectively.

COPS7A Antibody (C-term) - References

Matsuoka, S., et al. Science 316(5828):1160-1166(2007)
Stelzl, U., et al. Cell 122(6):957-968(2005)
Obuse, C., et al. Nat. Cell Biol. 6(11):1135-1141(2004)
Wolf, D.A., et al. Nat. Cell Biol. 5(12):1029-1033(2003)
Groisman, R., et al. Cell 113(3):357-367(2003)